{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T18:33:44Z","timestamp":1764873224652},"reference-count":16,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2012,7,4]],"date-time":"2012-07-04T00:00:00Z","timestamp":1341360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:p>Rituximab (<jats:styled-content style=\"fixed-case\">R<\/jats:styled-content>) plus doxorubicin, cyclophosphamide, vincristine, and prednisolone (<jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content>) chemotherapy (<jats:styled-content style=\"fixed-case\">R<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content>) is widely accepted as standard care for diffuse large <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>\u2010cell lymphoma (<jats:styled-content style=\"fixed-case\">DLBCL<\/jats:styled-content>) patients. The revised <jats:styled-content style=\"fixed-case\">I<\/jats:styled-content>nternational <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>rognostic Index (<jats:styled-content style=\"fixed-case\">R<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IPI<\/jats:styled-content>) was established in 2007 after the addition of rituximab to standard <jats:styled-content style=\"fixed-case\">DLBCL<\/jats:styled-content> treatment. To reassess the utility of <jats:styled-content style=\"fixed-case\">R<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IPI<\/jats:styled-content>, we carried out a retrospective analysis of patients with <jats:styled-content style=\"fixed-case\">DLBCL<\/jats:styled-content> uniformly treated with standard <jats:styled-content style=\"fixed-case\">R<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content>. Progression\u2010free survival (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>) curves in \u201cvery good\u201d and \u201cgood\u201d risk groups as defined by the <jats:styled-content style=\"fixed-case\">R<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IPI<\/jats:styled-content> showed no statistical difference. We added soluble interleukin\u20102 receptor (s<jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u20102<jats:styled-content style=\"fixed-case\">R<\/jats:styled-content>) level to the factors comprising the <jats:styled-content style=\"fixed-case\">R<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IPI<\/jats:styled-content>. Five levels of s<jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u20102<jats:styled-content style=\"fixed-case\">R<\/jats:styled-content> were weighed with respect to their impact on <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>. s<jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u20102<jats:styled-content style=\"fixed-case\">R<\/jats:styled-content> of &gt;2500\u00a0U\/mL was determined as the most appropriate threshold. We developed a new prognostic <jats:styled-content style=\"fixed-case\">SIL<\/jats:styled-content> index, which includes three independent prognostic risk factors: clinical stage (<jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>); s<jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u20102<jats:styled-content style=\"fixed-case\">R<\/jats:styled-content> level over 2500\u00a0U\/mL (<jats:styled-content style=\"fixed-case\">I<\/jats:styled-content>); and elevated lactate dehydrogenase level (<jats:styled-content style=\"fixed-case\">L<\/jats:styled-content>). This index indicates standard risk (0 or 1 risk factors, 4\u2010year <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> 83%, 4\u2010year overall survival 91%) and high risk (2 or 3 risk factors, 4\u2010year <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> 52%, 4\u2010year overall survival 67%) outcomes. The <jats:styled-content style=\"fixed-case\">SIL<\/jats:styled-content> index is a simple and objective prognostic index for <jats:styled-content style=\"fixed-case\">DLBCL<\/jats:styled-content> patients to identify candidates for experimental therapy other than <jats:styled-content style=\"fixed-case\">R<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content>. (<jats:italic>Cancer Sci<\/jats:italic>, doi: 10.1111\/j.1349\u20107006.2012.02331.x, 2012)<\/jats:p>","DOI":"10.1111\/j.1349-7006.2012.02331.x","type":"journal-article","created":{"date-parts":[[2012,5,16]],"date-time":"2012-05-16T07:07:23Z","timestamp":1337152043000},"page":"1518-1523","source":"Crossref","is-referenced-by-count":24,"title":["<scp>SIL<\/scp> index, comprising stage, soluble interleukin\u20102 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large <scp>B<\/scp>\u2010cell lymphoma"],"prefix":"10.1111","volume":"103","author":[{"given":"Naoto","family":"Tomita","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Clinical Immunology Yokohama City University Graduate School of Medicine Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rika","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Kanagawa Cancer Center Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Fujisawa","sequence":"additional","affiliation":[{"name":"Department of Hematology Yokohama City University Medical Center Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsumichi","family":"Fujimaki","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Immunology Fujisawa City Hospital Fujisawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Taguchi","sequence":"additional","affiliation":[{"name":"Department of Hematology Shizuoka Red Cross Hospital Shizuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chizuko","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Hematology Yamato City Hospital Yamato Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Hematology Yokosuka City Hospital Yokosuka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsuko","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Immunology Yokohama City University Graduate School of Medicine Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Ishigatsubo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Immunology Yokohama City University Graduate School of Medicine Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,7,4]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-038257"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.3131876"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.176.2.531"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn677"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10699"},{"key":"e_1_2_7_8_1","volume-title":"Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours","author":"Jaffe ES","year":"2001"},{"key":"e_1_2_7_9_1","volume-title":"WHO classification of tumors of haematopoietic and lymphoid tissues","author":"Swerdlow SH","year":"2008"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304083281404"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.131"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70235-2"},{"key":"e_1_2_7_14_1","unstructured":"Non Hodgkin's lymphoma Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network Inc. Available at:http:\/\/www.nccn.org(Accessed 24 March 2012)."},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807023390104"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.6929"},{"key":"e_1_2_7_17_1","article-title":"Prognostic impact of extranodal involvement in diffuse large B\u2010cell lymphoma in the rituximab era","author":"Takahashi H","journal-title":"Cancer"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2012.02331.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2012.02331.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T07:17:46Z","timestamp":1697440666000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2012.02331.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,4]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1111\/j.1349-7006.2012.02331.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2012.02331.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,4]]}}}